Tempus Wealth Planning LLC Buys Shares of 5,550 TransMedics Group, Inc. (NASDAQ:TMDX)

Tempus Wealth Planning LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,550 shares of the company’s stock, valued at approximately $346,000.

Several other institutional investors have also recently made changes to their positions in TMDX. Sachetta LLC acquired a new stake in shares of TransMedics Group during the fourth quarter valued at about $40,000. USA Financial Formulas acquired a new stake in TransMedics Group in the 3rd quarter valued at approximately $55,000. Quarry LP raised its position in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares during the period. National Bank of Canada FI lifted its stake in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after buying an additional 316 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $72.14 on Wednesday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market capitalization of $2.42 billion, a PE ratio of 76.75 and a beta of 2.12. The business’s fifty day moving average price is $67.09 and its 200 day moving average price is $111.20.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on TMDX. Robert W. Baird cut their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Piper Sandler lowered their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.